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Objectives
People with HIV (PWHIV) are likely to need therapies for comorbidities as they age. We assessed
risk of drug–drug interactions (DDIs) in PWHIV.
Methods
The Climate-HIV electronic recording system was used to cross-sectionally analyse records from
PWHIV aged ≥ 18 years attending four UK HIV units with a current antiretroviral (ARV)
prescription in February 2018. Antiretroviral and non-ARV medications were categorized by
clinical significance of DDIs (University of Liverpool DDI tool). Potential DDIs were predicted using
treatment guidelines for commonly recorded comorbidities.
Results
Among 4630 PWHIV (44% female), 41% were ≥ 50 years old. The average number of non-ARV
comedications increased from < 1 for patients aged ≤ 24 years to > 5 for patients aged ≥ 75 years;
65% were taking one or more non-ARV comedications. The median (interquartile range) number of
non-ARVs was 1 (0–2) and 2 (1–5) for those aged < 50 and ≥ 50 years, respectively. Common
comorbidities/concurrent health conditions occurred more frequently in patients aged ≥ 50 years
vs. < 50 (53% vs. 34%). Boosted protease inhibitors were associated with the highest proportion of
contraindicated comedications; dolutegravir and raltegravir had the fewest. For non-ARVs,
sildenafil and quetiapine were most likely to result in DDIs. Guideline-recommended treatments for
hepatitis C, hepatitis B, and tuberculosis had the highest proportions of contraindications when
combined with ARV regimens, while treatments for hepatitis C, malignancy, and mental health
conditions had the highest proportion of combinations potentially causing DDIs requiring dose
monitoring or adjustment.
Conclusions
Non-ARV use by PWHIV is high and increases with age. Treatment decisions for ageing PWHIV
should consider guideline recommendations for comorbidities.
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Introduction
The introduction of antiretroviral (ARV) medications has
led to substantial increases in the life span of people with
HIV (PWHIV) [1]. However, as PWHIV live longer, the
risk of developing additional health conditions that
require concomitant medications increases, and the man-
agement of these medications while on combination ARV
therapy is a challenging aspect of HIV care [2]. Older
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PWHIV with comorbidities are routinely prescribed multi-
ple medications and are likely to be managed by several
specialist physicians, each focusing on a single aspect of
their health [2,3]. This increases the risk of serious
adverse drug events and drug–drug interactions (DDIs)
[4]. Co-administration of multiple medications can also
affect adherence and, therefore, effectiveness of treatment
if not managed appropriately [2].
Real-world data indicate that up to 40% of PWHIV
have at least one potential DDI involving ARV medica-
tions, with interactions between protease inhibitors (PIs)
or nonnucleoside reverse transcriptase inhibitors (NNRTIs)
and central nervous system or cardiovascular drugs
accounting for the majority of DDIs in patients aged
≥ 50 years [5].
Some potential DDIs can be managed by dose adjust-
ment or monitoring (classified as amber according to the
University of Liverpool DDI tool used in this study), requir-
ing ongoing communication between clinicians and from
patients. Other DDIs may require a change to alternative
therapies for HIV or the associated comorbidities [6]. With
the introduction of regimens based on integrase strand
transfer inhibitors (INSTIs) such as dolutegravir (DTG), ral-
tegravir (RAL), and bictegravir, opportunities have arisen
to reduce the risk of DDIs associated with PIs and NNRTIs
[7]. Additionally, using DTG-based two-drug regimens to
manage HIV may reduce the risk of associated DDIs.
Recognition of DDIs in real-world settings can be chal-
lenging [8]. Care record systems for clinical management
of PWHIV are often separate from the main hospital
health record for confidentiality reasons, and records of
prescriptions issued in general practice or other clinical
settings may not be captured reliably. With patients liv-
ing longer and having greater access to medicines (in-
cluding online, over-the-counter, and prescribed by
healthcare professionals), there is an increased risk of
DDIs when prescribing ARV medications without an
accurate and up-to-date drug history. Real-world analy-
ses of prescriptions of concomitant medication and DDIs
with ARV therapy are generally lacking, particularly in
women and minorities. The purpose of this study was to
evaluate the types of concomitant medications used with
ARV therapy and to explore the risk of DDIs associated




This was a cross-sectional analysis of PWHIV receiving
care at participating hospital trusts using Climate-HIV, an
electronic patient record system used to manage PWHIV,
conducted from December 2012 through March 2018. Cli-
mate-HIV is updated in real time and contains patient
information recorded by the multidisciplinary team,
including referral letters, diagnostic information, and
drug histories. Patient information is collected and manu-
ally entered by the specialist pharmacist during the clinic
appointment. For this study, data were included from
North Middlesex University Hospital NHS Trust, Notting-
ham University Hospitals NHS Trust, Birmingham Heart-
lands Hospital, and Homerton University Hospital NHS
Foundation Trust.
Potential interactions between ARV medications and
guideline-recommended therapies for other conditions
were reported [e.g. guideline treatment recommendations
for diabetes include metformin, which the University of
Liverpool DDI tool indicates has no interaction with the
ARV medication efavirenz (EFV)]. The proportion of indi-
viduals with documented health conditions as recorded
by their physician in Climate-HIV was also reported.
Patients
All PWHIV included in the study had a recorded diagno-
sis of HIV-1; were aged ≥ 18 years at the index date;
were registered at the clinic (or had a record within the
18 months before the index date); were prescribed an
ARV regimen within the year before the index date; and
had a current ARV prescription in February 2018. The
study period included data from the time of patient
record entry into Climate-HIV. The index date was the
most recent record in Climate-HIV and was required to
be within 18 months before data extraction. The most
recent record rather than the most recent ARV prescrip-
tion was used in the analyses, allowing inclusion of
potential concomitant non-ARV therapies prescribed after
or added to the last ARV medication.
Assessment of DDIs
All ‘current’ medications/drug treatments were included
in the analysis of DDIs. Drug–drug interactions between
ARV and non-ARV medications were determined using
University of Liverpool HIV interactions database [9] and
categorized as red (do not co-administer), amber (poten-
tial interaction; may be managed by dose adjustment or
monitoring), yellow (potential interaction likely to be of
weak intensity; unlikely to require dose adjustment or
additional monitoring), and green (no interaction
expected) [6].
Drug–drug interaction charts by ARV class and comed-
ication were cross-tabulated against medications observed
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at the patient and population level using R version 3.5.1
(The R Foundation for Statistical Computing, Vienna,
Austria).
Statistical analysis
Patient characteristics, including sex, ethnicity, and age,
as well as time from HIV diagnosis to index date, were
summarized using descriptive statistics [median and
interquartile range (IQR); Table 1].
Patient- and interaction-level DDIs
The number of non-ARV therapies at baseline was
described, in addition to the number of concomitant ther-
apies [category, mean (SD), and median (IQR)]. The num-
ber and type of health conditions were similarly
determined [n (%), mean (SD), and median (IQR)]. The
number of patients without any recorded non-ARV medi-
cations was also determined. For patients with non-ARV
medications, DDIs with ARV medications were identified,
and the analyses were stratified by age group (< 50 and
≥ 50 years). The proportions of the study population with
red, amber, yellow, and green interactions were reported,
as well as the proportion of interactions for each regimen
of each colour.
A stepwise logistic regression model was derived to
determine which factors increased the odds of a red or
amber interaction based on the observed ARV/non-ARV
medications in the overall population. Because of the low
frequency of red interactions observed in the study popu-
lation, red and amber interactions were given an equal
weighting in the model. Age (< 50 and ≥ 50 years), sex,
current ARV regimen, number of concomitant drugs, and
the presence of any comorbidity or concurrent health
condition were included in the baseline model. Stepwise
selection was then used to choose other variables for
selection. Initially, individual comorbidities/health condi-
tions and ethnicity were also included; however, these
variables were removed from the final model because of
under-reporting and collinearity, respectively. Aside from
ethnicity, no other variables exhibited collinearity. The
model with the lowest Akaike information criterion was
selected.
Theoretical DDIs
To evaluate the propensity for DDIs in PWHIV when
adhering to clinical guidelines for treating common
comorbidities/health conditions, we first identified those
occurring at high prevalence in the UK Climate-HIV data-
base as follows: type 2 diabetes, hypertension, hyperlipi-
daemia, chronic obstructive pulmonary disease, asthma,
chronic kidney disease, hepatitis B, hepatitis C, malig-
nancy, tuberculosis, cardiovascular disease, peripheral
neuropathy, osteoporosis, and mental health disorders
(depression, anxiety, bipolar disorder, schizophrenia,
mania, and psychosis). Next, we selected recommended
first-line comedications based on adherence to UK
National Institute for Health and Care Excellence (NICE)
treatment guidelines. Finally, we evaluated the likelihood
of DDIs with the ARV regimens currently used in our
study population, using the University of Liverpool DDI
tool. For the high-prevalence comorbidities, the propor-
tion of possible interactions [n (%) of red, amber, yellow,
and green interactions for each condition] with the
observed medication groups was determined. This analy-
sis represented theoretical DDIs encountered if neither the




The study population included 4630 PWHIV (Table 1);
median time since HIV diagnosis or transfer into an HIV
clinic using Climate-HIV was 11 years (IQR: 5.7–15.7),
and patients had received a median of 3 (IQR: 2–5) previ-
ous ARV regimens.
Antiretroviral medications and regimens
Overall, 96% of patients had three or more ARV medica-
tions in their regimen, excluding ritonavir or cobicistat
[median = 3 (IQR: 3–3)], and all regimens were composed
of two nucleoside reverse transcriptase inhibitors (NRTIs)
plus a third agent. When ARV regimens were grouped by
the third agent, the largest proportion of patients were
taking EFV + two NRTIs (23%, n = 1049), followed by
DTG + two NRTIs (18%, n = 826). Overall, the most




Sex, female [n (%)] 2021 (44)
Race/ethnicity [n (%)]
Black, African heritage 2064 (45)
White 1582 (34)
Black, Caribbean heritage/other 446 (10)
Asian 155 (3)
Mixed/unknown 383 (8)
Age, median (IQR) (years) 47 (39–54)
Age ≥ 50 years at baseline [n (%)] 1898 (41)
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frequently recorded ARV regimens were EFV/emtric-
itabine (FTC)/tenofovir disoproxil fumarate (TDF) (18%,
n = 811); DTG/abacavir (ABC)/lamivudine (3TC) (14%,
n = 644); and rilpivirine (RPV)/FTC/TDF (7%, n = 308). A
larger proportion of patients aged < 50 years were taking
DTG/ABC/3TC than patients aged ≥ 50 years (18% vs.
8%; Table 2).
Concomitant medications
Overall, 65% of patients (n = 2992) were taking ≥ 1 non-
ARV medication, and 17% (n = 770) were taking ≥ 5
non-ARV medications (Table 3). Among patients aged
≥ 50 years, 27% (n = 508) were taking ≥ 5 non-ARV
medications, compared with 10% (n = 262) of patients
aged < 50 years (P < 0.0001). Similarly, a higher propor-
tion of patients aged < 50 years were taking no comedi-
cations compared with those aged ≥ 50 years (43% vs.
24%). The most frequently recorded non-ARV medica-
tions were cholecalciferol (25%), atorvastatin (9%), and
co-trimoxazole (9%). Differences in non-ARV medications
were noted between patients aged < 50 vs. ≥ 50 years,
where the use of atorvastatin (3% vs. 19%), amlodipine
(4% vs. 12%), and ramipril (2% vs. 11%) increased with
age (Table 3).
Comorbid or concurrent health conditions
Overall, 40% (n = 1838) of patients had one or more
comorbid or concurrent health conditions, with a lower
proportion of patients aged < 50 years recording one or
more comorbidity/health conditions compared with those
aged ≥ 50 years (32% vs. 50%). The median number of
health conditions in addition to HIV was 0 (IQR: 0–1) for
patients aged < 50 years and 1 (IQR: 0–1) for those aged
≥ 50 years. Among selected health conditions, the most
prevalent were hepatitis B, mental health disorders, and
hypertension (6% each). The prevalence of hypertension
demonstrated the most pronounced difference between
patients aged < 50 years and those aged ≥ 50 years,
affecting 3% of younger patients vs. 10% of older
patients (Table 3). Assessment of combinations of comor-
bid/concurrent health conditions indicated that diabetes
and hypertension were the most frequent combination











Number of pills in current
ARV regimen, median
(IQR)




3 (3–3) 3 (3–3) 3 (3–3)
ARV regimens [n (%)]
EFV + two NRTIs 1049 (23) 602 (22) 447 (24)
DTG + two NRTIs 826 (18) 582 (21) 244 (13)
RPV + two NRTIs 308 (7) 212 (8) 96 (5)
NVP + two NRTIs 392 (8) 205 (8) 187 (10)
RAL + two NRTIs 332 (7) 169 (6) 163 (9)
EVG/c + two NRTIs 89 (2) 69 (3) 20 (1)
ATV/r/c + two NRTIs 188 (4) 122 (4) 66 (3)
DRV/r/c + two NRTIs 653 (14) 436 (16) 217 (11)
DRV/r/DTG 31 (1) 12 (< 1) 19 (1)
ATV, atazanavir; c, cobicistat; DRV, darunavir; DTG, dolutegravir; EFV,
efavirenz; EVG, elvitegravir; IQR, interquartile range; NRTI, nucleoside
reverse transcriptase inhibitor; NVP, nevirapine; r, ritonavir; RAL, ralte-
gravir; RPV, rilpivirine.







Age < 50 years
(N = 2732)













1 (0–3) 1 (0–2) 2 (1–5)
Most commonly reported (≥ 5%) concomitant non-ARV medications [n
(%)]
Cholecalciferol 1162 (25) 668 (24) 494 (26)
Atorvastatin 424 (9) 72 (3) 352 (19)
Co-trimoxazole 418 (9) 247 (9) 171 (9)
Amlodipine 325 (7) 96 (4) 229 (12)
Salbutamol 325 (7) 151 (6) 174 (9)
Ramipril 266 (6) 66 (2) 200 (11)
Lansoprazole 253 (5) 95 (3) 158 (8)
Paracetamol 220 (5) 84 (3) 136 (7)
Comorbid/concurrent health conditions










0 (0–1) 0 (0–1) 1 (0–1)
Most commonly reported (≥ 5%) comorbid/concurrent health conditions [n
(%)]
Hepatitis B 290 (6) 154 (6) 136 (7)
Mental health
condition
282 (6) 147 (5) 135 (7)
Hypertension 271 (6) 80 (3) 191 (10)
Tuberculosis 230 (5) 131 (5) 99 (5)
Pregnancy† 207 (10) 180 (13) 27 (4)
ARV, antiretroviral; IQR, interquartile range.
†
N = 2021 for overall study population; N = 1334 for patients aged
< 50 years; and N = 687 for patient aged ≥ 50 years.
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(1% of patients overall), increasing from < 1% in patients
aged < 50 years to 2% in those aged ≥ 50 years.
Patient-level DDIs
Drug–drug interactions were assessed at the patient level
using the University of Liverpool DDI tool and catego-
rized by colour. In total, 40 red and 1458 amber DDIs
were observed in this patient population. Sildenafil and
quetiapine were most frequently associated with red
interactions, with sildenafil resulting in a red interaction
for 18 (5.3%) patients taking ritonavir- or cobicistat-
boosted darunavir (DRV/r/c) + two NRTIs and quetiapine
resulting in a red interaction for four (1.2%) patients tak-
ing the same regimen. Red interactions were also identi-
fied with lansoprazole for three (5.5%) patients taking a
regimen of RPV + two NRTIs; with omeprazole for two
(2.7%) patients taking a regimen of ATV/r/c + two NRTIs;
and with norethisterone, desogestrel, and etonogestrel,
each for two (0.4%) patients taking a regimen of
EFV + two NRTIs. Cholecalciferol and atorvastatin
accounted for the greatest proportion of amber interac-
tions.
In a logistic regression model, compared with
DTG + two NRTIs, all regimens [aside from RPV + two
NRTIs (data not shown)] significantly increased the risk
of red or amber DDIs (P < 0.002; Fig. 1). The most pro-
nounced increased risk was for elvitegravir [EVG/c; odds
ratio (OR) = 8.5 (95% CI: 3.9–18.8)] and atazanavir [ATV/
r/c; OR = 5.8 (95% CI: 3.4–10.0)]. Addition of a single
non-ARV medication [OR = 1.3 (95% CI: 1.2–1.3)] and a
comorbid diagnosis [OR = 1.4 (95% CI: 1.2–1.7)] also
increased the risk of DDIs by at least 28%, irrespective of
ARV regimen. Age and sex did not influence the risk of
DDI; however, the number of concomitant non-ARV
medications did increase with age, and this factor was
significant but not collinear [OR = 1.3 (95% CI: 1.2–1.3)].
Interaction-level DDIs
A separate analysis of DDIs was conducted at the interac-
tion level based on the observed combinations of ARV/
non-ARV medications. The prescribed non-ARV medica-
tions observed for all patients taking each ARV regimen
were cross-tabulated to summarize the proportion of col-
our classifications. Figure 2 shows the proportion of non-
ARV medications that had an interaction or did not inter-
act with the ARV medication of interest. The denomina-
tors are the number of different non-ARV medications
recorded by patients taking each of the regimens. The
highest proportion of red or amber interactions occurred
with ATV/r/c + two NRTIs (58%, n = 57), followed by
DRV/r/c + two NRTIs (48%, n = 128). DTG + two NRTIs
(87%, n = 194) and RAL + two NRTIs (84%, n = 147) had
the greatest proportion of green medication combinations
(Fig. 2a).
Rates of DDIs with DTG were similar between patients
aged ≥ 50 years and those aged < 50 years (14% each;
Fig. 2b). Results were comparable for patients taking
RAL-based regimens, where DDIs were identified for 14%
of the comedication pairings for patients aged ≥ 50 years
and for 18% of those aged < 50 years; however, there
was a higher proportion of DDIs classified as amber
(drugs that potentially interact) among patients aged
≥ 50 years than among those aged < 50 years (14% vs.
10%; Fig. 2b). Overall, the slightly higher rates of
observed amber and yellow DDIs with RAL compared
with DTG (13% vs. 15%; Fig. 2a) can be attributed to the
more frequent prescription of TDF/FTC with RAL vs.
ABC/3TC with DTG.
Propensity for DDIs with common comorbidities/
concurrent health conditions
Table 4 illustrates that for the common comorbidities/
concurrent health conditions, adherence to NICE-recom-
mended guidelines yielded the greatest potential risk of
DDIs in patients with hepatitis C co-infection, with red
(22%) and amber (58%) interactions across all current
ARV regimens. Additionally, 50% of treatment combina-
tions for malignancy and 32% for mental health condi-
tions resulted in amber interactions.
Discussion
In this large cross-sectional study, we evaluated DDIs in a
population of PWHIV in the UK using data from Climate-
HIV. The results confirm previous findings, demonstrating
that polypharmacy and the risk of DDIs in PWHIV
increase with age [5]. This study represents one of the
largest, real-world, heterogeneous populations of PWHIV
in which DDIs were evaluated. Of the overall population
in this study, 2021 patients (44%) were women, 3048
(66%) were non-white, and 1898 (41%) were aged
≥ 50 years. This is in comparison with previous studies
evaluating DDIs in PWHIV, which have focused on popu-
lations that are predominantly white and male [5,10].
Most PWHIV are treated with regimens composed of
three ARV drugs; therefore, only two additional medica-
tions would result in polypharmacy according to the most
commonly used definition (≥ 5 drugs) [11]. In this study,
47% (2195/4630) of patients were taking at least two
non-ARV drugs, and the proportion was higher [61%
(1154/1898)] for patients aged ≥ 50 years compared with
© 2020 The Authors.
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those aged < 50 years [38% (1041/2732)]. In addition to
an increased risk of DDIs, polypharmacy is associated
with worst reported outcomes, including elevated risk of
adverse drug reactions and non-adherence in the general
population and increased risk of geriatric syndromes such
as falls, fractures, and dementia in the elderly population
[2,12,13].
In this study, the most prevalent recorded comorbidities
were hepatitis B, mental health conditions and hyperten-
sion (6% each); this differs from the results of a previous
real-world study that indicated much higher prevalence of
hepatitis B (24%), mental health conditions (22%), cardio-
vascular disease (20%), hepatitis C (14%), and diabetes
(11%) in PWHIV [14]. In the present study, clinicians
recorded patient-reported prescriptions received outside of
the participating hospital as well as over-the-counter
medications in Climate-HIV; however, as these are
patient-reported clinician-entered data, they may not have
always been captured reliably, potentially leading to
under-reporting of comorbidities. For instance, under-re-
ported use of proton pump inhibitors, which are con-
traindicated in patients receiving RPV, could have resulted
in under-reported DDIs. However, while non-ARV use
overall may have been under-estimated, the relative risks
of DDIs for different ARV regimens are not expected to be
affected, representing a strength of this study.
Despite the possibility of under-reporting, mental
health conditions were among the most commonly
reported comorbidities, and approximately one in three
(32%) of the therapies used for mental health conditions
resulted in an amber DDI. Conversely, this observation is
consistent with other studies reporting that mental health
problems are the most prevalent comorbidities in HIV,
with 39–57% of patients having received a mental health
diagnosis within the previous 2 years [15,16]. As medica-
tions for mental health conditions are most likely to be
prescribed by a psychiatrist, they may not appear in med-
ical records for primary care, increasing the risk of inad-
vertent prescription of interacting drugs. An additional
risk that was not recorded in this study is the potential
for DDIs when dosages are altered. In this situation, the
drug itself remains the same but the change in dosage
may lead to a DDI; an alteration may not have been
observed until the next clinic appointment with another
specialist qualified to amend the dosage or withdraw any
interacting drugs.
This analysis found frequent red interactions at the
patient level when cross-tabulating the commonly pre-
scribed drug quetiapine with common ARV regimens,
though notably, no DDIs are expected between quetiapine
and DTG-, RAL-, or RPV-based regimens [17].
The number of concomitant non-ARV medications
tended to increase as patients aged, suggesting an
increased presence of comorbid conditions. A previous
study also found that comedication use among PWHIV in
Switzerland tended to increase with age [5]. Our results
indicate that the addition of one non-ARV medication or
the presence of any comorbidity or concurrent health
OR Lower CL Upper CL P value
1.13 0.92 1.38 0.2384
0.94 0.78 1.15 0.5676
5.84 3.41 9.99 < 0.0001
4.83 3.54 6.59 < 0.0001
2.53 1.90 3.37 < 0.0001
8.50 3.85 18.75 < 0.0001
1.82 1.31 2.54 0.0004
1.77 1.24 2.52 0.0016
0.76 0.49 1.19 0.2292
1.27 1.22 1.33 < 0.0001
1.40 1.15 1.70 0.0008
Age >50 (vs. <50) years
Female
Atazanavir/r/c + 2 NRTIs
Darunavir/r/c + 2 NRTIs
Efavirenz + 2 NRTIs
Elvitegravir/c + 2 NRTIs
Nevirapine + 2 NRTIs
Raltegravir + 2 NRTIs
Rilpivirine + 2 NRTIs
Addition of a single
concomitant non-ARV
Presence of any comorbidity
Odds ratio
1 3 5 7 9 11 13 15 17 19
Fig. 1 Logistic regression analysis assessing factors influencing the risk of red or amber drug–drug interactions relative to regimens based on
dolutegravir. For odds ratios (ORs) associated with antiretroviral (ARV) regimens, the reference regimen is dolutegravir. The symbol size repre-
sents the relative number of patients. c, cobicistat; CL, confidence level; NRTI, nucleoside reverse transcriptase inhibitor; r, ritonavir.
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ATV/r/c + 2 NRTIs
(N = 57)
DRV/r/c + 2 NRTIs
(N = 128)
DTG + 2 NRTIs
(N = 194)
EFV + 2 NRTIs
(N = 154)
EVG/c + 2 NRTIs
(N = 54)
NVP + 2 NRTIs
(N = 139)
RAL + 2 NRTIs
(N = 147)
RPV + 2 NRTIs
(N = 94)
ATV/r/c + 2 NRTIs
(N = 57)
DRV/r/c + 2 NRTIs
(N = 128)
DTG + 2 NRTIs
(N = 194)
EFV + 2 NRTIs
(N = 154)
EVG/c + 2 NRTIs
(N = 54)
NVP + 2 NRTIs
(N = 139)
RAL + 2 NRTIs
(N = 147)






























































































































Do not co-administer Potential interaction Potential weak interaction No interaction expected
Fig. 2 Proportion of potential drug-drug interactions based on observed non-antiretroviral (non-ARV) medications taken with ARV regimens
(a) in the overall population and (b) stratified by patient age. All regimens listed are taken with two nucleoside reverse transcriptase inhibitors
(NRTIs). N represents the number of non-ARV medications recorded by the population using each specific regimen. ATV, atazanavir; c, cobicis-
tat; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; EVG, elvitegravir; NVP, nevirapine; r, ritonavir; RAL, raltegravir; RPV, rilpivirine.
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condition significantly increased the risk of a red or
amber DDI. Overall, regimens based on ATV/r/c or DRV/
r/c tended to represent the greatest proportion of patients
experiencing red or amber interactions, and the propor-
tion of red and amber interactions also increased with
age; regimens based on boosted EVG demonstrated a sim-
ilar pattern. These regimens were also associated with a
greater likelihood of DDI in logistic regression when
compared with DTG, as were regimens based on EFV,
nevirapine, and RAL (P < 0.05). Dolutegravir and RAL
were associated with the highest proportion of green
interactions and had no potential red interactions
observed.
These results are consistent with previous studies
reporting the risks of potential DDIs for PWHIV treated
with various ARV regimens. In an analysis from the
Swiss HIV Cohort Study, PI- and NNRTI-based therapies
were associated with an increased risk of potential DDIs
[5]. In a cohort study of PWHIV aged > 65 years treated
in France, an increased risk of red DDIs was observed
with boosted PIs or EVG (adjusted OR vs. NNRTI-based
regimens, 4.12; 95% CI: 3.34–5.10; P < 0.0001) and a
decreased risk was observed with DTG- or RAL-based
regimens (adjusted OR = 0.02; 95% CI: 0.005–0.050;
P < 0.0001) [18]. Another recent population-based study
evaluated risk of DDIs in PWHIV in a drug-dispensing
registry in Madrid, Spain [19]. The greatest risk of red
interactions was observed with boosted DRV, while treat-
ment with unboosted INSTI-based regimens was statisti-
cally significantly associated with a reduced risk of red
interactions (adjusted OR = 0.72; 95% CI: 0.60–0.88;
P = 0.001) [19].
The majority of guideline-recommended therapies for
treatment of chronic conditions do not consider
concurrent conditions. Per the NICE guidelines, the rec-
ommended therapies for hepatitis C, hepatitis B, and
tuberculosis generated the highest proportions of red
DDIs when administered in combination with ARVs.
Additionally, recommended therapies for hepatitis C,
malignancy, and mental health conditions generated the
greatest proportion of amber DDIs, suggesting that these
comorbidities require the most interpretation and moni-
toring by clinicians. However, when reviewing the
observed non-ARVs at the patient level, the lipid-lower-
ing medication atorvastatin, the calcium channel blocker
amlodipine, and the vasodilator sildenafil were among
the most common concomitant medications in this study.
These medicines were associated with red, amber or yel-
low DDIs for most ARV regimens and are all used for the
management of cardiovascular disease.
Understanding the classification of DDIs is important
for prescribing clinicians, particularly for the red and
amber classifications. The red classification designates
specific medications that should not be prescribed
together. However, the amber classification allows for
greater interpretation by the specialist clinician, and the
possible dose adjustment and/or monitoring may be asso-
ciated with greater inter- and intrapatient variability.
Therefore, the amber classification may require more
interpretation from the multidisciplinary team and better
communication with patients. Overall, there were more
amber DDI classifications than red or yellow in this
study.
This study has several limitations. Data were derived
from four selected UK sites and may not be representative
of the entire population with HIV in the UK. Concordance
between comedications and health conditions was not
assessed in this analysis. Additionally, it is unclear
whether some potential DDIs identified in this study were
managed with dose adaptation, as this would require a
longitudinal analysis. Furthermore, we were unable to
assess for actual clinical harms resulting from these
potential DDIs as data were not collated at a patient level.
However, it could be assumed that DDIs classified as red
would likely lead to clinical harm. Finally, patients
reported prescriptions received outside of the participat-
ing hospital along with over-the-counter medications to
the clinician at each visit; however, some of these medi-
cations may not have been reported as patients may not
have been asked by the clinician, patients may have
failed to accurately recall them, or prescriptions may
have been incorrectly coded when entered into the data-
base. Therefore, medications and comorbidities that were
not recorded in the Climate-HIV database may have
resulted in misclassification or missing prescription data
and under-reporting of DDIs.
Table 4 Proportion of antiretroviral/non-antiretroviral combinations
resulting in drug–drug interactions based on National Institute for
Health and Care Excellence-recommended therapies for selected
health conditions
Condition Red (%) Amber (%) Yellow (%)
Hepatitis C 22 58 0
Hepatitis B 20 20 0
Tuberculosis 14 14 0
Cardiovascular disease 5 23 9
Hyperlipidaemia 4 14 10
Mental health 3 32 19
COPD 3 13 8
Asthma 3 12 9
Hypertension 2 19 9
Peripheral neuropathy 1 23 19
Malignancy 0 50 4
Diabetes 0 31 2
Chronic kidney disease 0 3 13
COPD, chronic obstructive pulmonary disorder.
© 2020 The Authors.
HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association
HIV Medicine (2020)
8 C Okoli et al.
This study represents one of the largest, real-world,
heterogeneous populations of PWHIV (44% women, 66%
non-white) in which DDIs were evaluated. This analysis
demonstrated that the use of comedications in PWHIV is
high and increases with age, resulting in an elevated risk
of polypharmacy and DDIs, which is similar to previous
findings from clinical trials and other real-world popula-
tions [5,10]. In countries like the UK, most PWHIV on
ARVs have undetectable viral loads, see their HIV clini-
cian once or twice annually, and have greater access to
medicines over the counter and online. Therefore, efforts
to increase communication between healthcare profes-
sionals, empower patients and reduce drug burden should
be seriously pursued. The results of this study reinforce
the importance of ongoing and up-to-date reviews of
concomitant medications and comorbidities when seeing
a patient in clinic and choosing ARV regimens that can
mitigate the associated risks of polypharmacy and DDIs.
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